Search

Your search keyword '"Ciuffreda, Lucia"' showing total 10 results
Start Over Author "Ciuffreda, Lucia"
10 results on '"Ciuffreda, Lucia"'

1. Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy

Author

Strafella, Vanda, Attolico, Immacolata, Carluccio, Paola, Tarantini, Francesco, Curci, Paola, Sgherza, Nicola, Rizzi, Rita, Ostuni, Angelo, Buda, Gabriele, Del Giudice, Maria Livia, Marasco, Vincenzo, Mele, Anna, Margiotta-Casaluci, Gloria, Valli, Viviana Beatrice, Mele, Giuseppe, Germano, Candida Rosaria, Quinto, Angela Maria, Palazzo, Giulia, Febbo, Massimiliano Arangio, Ciuffreda, Lucia, Reddiconto, Giovanni, Di Renzo, Nicola, Cimminiello, Michele, Albano, Francesco, and Musto, Pellegrino

Published
2024
Full Text
View/download PDF

2. Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Author

Offidani, Massimo, primary, Zizzo, Carmela, additional, Rupoli, Serena, additional, Federici, Irene, additional, Morè, Sonia, additional, Bossi, Alessandra, additional, Manieri, Valentina Maria, additional, Petrucci, Maria Teresa, additional, Caravita DI Toritto, Tommaso, additional, Brunori, Marino, additional, Gozzetti, Alessandro, additional, Tordi, Attilio, additional, Fazio, Francesca, additional, Lisi, Chiara, additional, Melaccio, Assunta, additional, Ciuffreda, Lucia, additional, Falcone, Antonietta Pia, additional, Fioritoni, Francesca, additional, Gentili, Silvia, additional, Siniscalchi, Agostina, additional, Trastulli, Fabio, additional, Corvatta, Laura, additional, Morsia, Erika, additional, Olivieri, Attilio, additional, and Duro, Giovanni, additional

Published
2022
Full Text
View/download PDF

3. P-149: Prevalence of type 1 Gaucher disease in patients with multiple myeloma: interim analysis of a prospective, multicentre, observational study

Author

Offidani, Massimo, primary, Zizzo, Carmela, additional, Rupoli, Serena, additional, Federici, Irene, additional, Morè, Sonia, additional, Bossi, Alessandra, additional, Manieri, Valentina Maria, additional, Petrucci, Maria Teresa, additional, di Toritto, Tommaso Caravita, additional, Brunori, Marino, additional, Gozzetti, Alessandro, additional, Tordi, Attilio, additional, Fazio, Francesca, additional, Lisi, chiara, additional, Melaccio, Assunta, additional, Ciuffreda, Lucia, additional, Falcone, Antonietta Pia, additional, Fioritoni, Francesca, additional, Gentili, Silvia, additional, Siniscalchi, Agostina, additional, Trastulli, Fabio, additional, Morsia, Erika, additional, Corvatta, Laura, additional, Olivieri, Attilio, additional, and Duro, Giovanni, additional

Published
2022
Full Text
View/download PDF

4. Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Author

Offidani, Massimo, Zizzo, Carmela, More', Sonia, Federici, Irene, Bossi, Alessandra, Manieri, Valentina Maria, Petrucci, Maria Teresa, Fazio, Francesca, Lisi, Chiara, Farina, Francesca, Brunori, Marino, Fioritoni, Francesca, Sgherza, Nicola, De Francesco, Rosa, Caravita di Toritto, Tommaso, Tordi, Attilio, Amendola, Angela, Melaccio, Assunta, Gentili, Silvia, Ciuffreda, Lucia, Del Giudice, Maria Livia, Falcone, Antonietta Pia, Gozzetti, Alessandro, Tomassetti, Simona, Mele, Anna, Ruggieri, Miriana, Siniscalchi, Agostina, Bianco, Rosario, Greco, Antonino, Solimando, Antonio Giovanni, Rotondo, Francesco, Trastulli, Fabio, Corvatta, Laura, Morsia, Erika, Rupoli, Serena, Kordasti, Shahram, Olivieri, Attilio, and Duro, Giovanni

Published
2023
Full Text
View/download PDF

8. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

Author

Musto, Pellegrino, Maurillo, Luca, Spagnoli, Alessandra, Gozzini, Antonella, Rivellini, Flavia, Lunghi, Monia, Villani, Oreste, Aloe Spiriti, Maria Antonietta, Venditti, Adriano, Santini, Valeria, Leone, Giuseppe, Voso, Maria Teresa, D'Arco, Alfonso Maria, Tatarelli, Caterina, Ferrero, Dario, Gaidano, Gianluca, Palumbo, Giuseppe, Di Raimondo, Francesco, Oliva, Esther, Sanpaolo, Grazia, Tonso, Anna, Santagostino, Alberto, Filardi, Nunzio, Pollio, Berardino, Candoni, Anna, Fili, Carla, Russo, Domenico, Orciuolo, Enrico, Petrini, Mario, Ciuffreda, Lucia, Riezzo, Antonio, Morabito, Fortunato, Mazza, Patrizio, Pastore, Domenico, Specchia, Giorgina, and Ferrara, Felicetto

Subjects
Azacitidine, Hypomethylating agents, International prognostic, Myelodysplastic syndromes, Prognosis, Scoring system, Transfusion, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Drug Evaluation, Female, Humans, Italy, Male, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Risk, Treatment Outcome, Cancer Research, Oncology, Antimetabolites, 80 and over, hypomethylating agents, Antineoplastic, myelodysplastic syndromes, International Prognostic Scoring System, medicine.drug, medicine.medical_specialty, azacitidine, medicine.drug_class, Lower risk, Antimetabolite, Internal medicine, azacitidine,hypomethylating agents,myelodysplastic syndromes,prognosis,International Prognostic Scoring System,transfusion, medicine, Risk factor, Adverse effect, transfusion, business.industry, Retrospective cohort study, medicine.disease, Surgery, prognosis, business, Settore MED/15 - Malattie del Sangue
Abstract

BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high-risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have lower risk MDS. METHODS: The authors retrospectively evaluated 74 patients with International Prognostic Scoring System low-risk or intermediate 1-risk MDS, who received azacitidine on a national named patient program. At baseline, 84% of patients were transfusion-dependent, 57% had received erythropoietin, and 51% were aged > 70 years. Azacitidine was administered subcutaneously for 5 days (n ¼ 29 patients), 7 days (n ¼ 43 patients), or 10 days (n ¼ 2 patients) every month at a dose of 75 mg/m2 daily (n ¼ 45 patients) or at a fixed dose of 100 mg daily (n ¼ 29 patients) and for a median of 7 cycles (range, 1-30 cycles). RESULTS: According to the 2006 International Working Group criteria, overall response rate (ORR) was 45.9%, including complete responses (10.8%), partial responses (9.5%), hematologic improvements (20.3%), and bone marrow complete responses (5.4%).The ORR was 51.6% in 64 patients who completed at least 4 cycles of treatment. The median duration of response was 6 months (range, 1-30 months). After a median follow-up of 15 months, 71% of patients remained alive. A survival benefit was observed in responders versus nonresponders (94% vs 54% of patients projected to be alive at 2.5 years, respectively; P < .0014). The most common grade 3 or 4 adverse events were myelosuppression (21.6%) and infection (6.8%). CONCLUSIONS: The current results indicated that azacitidine may be a feasible and effective treatment for patients with lower risk MDS.

Published
2010

9. 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Author

Musto, Pellegrino, primary, Maurillo, Luca, primary, Spagnoli, Alessandra, primary, Gozzini, Antonella, primary, Rivellini, Flavia, primary, Tatarelli, Caterina, primary, Lunghi, Monia, primary, Fili, Carla, primary, Orciuolo, Enrico, primary, Ciuffreda, Lucia, primary, Vigna, Ernesto, primary, Cioppa, Paola Della, primary, Candoni, Anna, primary, Ferrero, Dario, primary, Palmieri, Salvatore, primary, Palumbo, Giuseppe, primary, Di Renzo, Nicola, primary, Oliva, Esther, primary, Sanpaolo, Grazia, primary, Pastore, Domenico, primary, Tonso, Anna, primary, Santagostino, Alberto, primary, Rocco, Stefano, primary, Villani, Oreste, primary, D’Auria, Fiorella, primary, D’Arco, Alfonso Maria, primary, Gaidano, Gianluca, primary, Galimberti, Sara, primary, Russo, Domenico, primary, Venditti, Adriano, primary, Aloe-Spiriti, Maria Antonietta, primary, Leone, Giuseppe, primary, and Santini, Valeria, primary

Published
2008
Full Text
View/download PDF

10. Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study.

Author

Morè S, Federici I, Bossi A, Rupoli S, Morsia E, Manieri VM, Olivieri A, Petrucci MT, Fazio F, Lisi C, Sorella S, Paoli AD, Farina F, Mele A, De Francesco R, Greco A, Fioritoni F, Liberatore C, De Toritto TC, Tordi A, Siniscalchi A, Brunori M, Sgherza N, Musto P, Amendola A, Vacca A, Solimando AG, Melaccio A, Palma A, Melillo LMA, Ciuffreda L, Gentili S, Buda G, Del Giudice ML, Falcone AP, Tosi P, Tomassetti S, Rotondo F, Gozzetti A, Galieni P, Ruggieri M, Frigeri F, Bianco R, Lombardo A, Trastulli F, Corvatta L, Zizzo C, Duro G, and Offidani M

Abstract

Competing Interests: The authors declare no conflict of interest.

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results